Gibson A - Search Results

1

Association of Early Anatomic Response with Visual Function in Neovascular Age-Related Macular Degeneration.

Singer M, Singh RP, Gibson A, Moini H, Reed K, Vitti R, Du W, Eichenbaum D. Singer M, et al. Among authors: gibson a. Ophthalmology. 2021 Nov;128(11):1657-1660. doi: 10.1016/j.ophtha.2021.05.011. Epub 2021 May 18. Ophthalmology. 2021. PMID: 34019956 Free article. No abstract available.

2

Applying the CONSORT and STROBE statements to evaluate the reporting quality of neovascular age-related macular degeneration studies.

Fung AE, Palanki R, Bakri SJ, Depperschmidt E, Gibson A. Fung AE, et al. Among authors: gibson a. Ophthalmology. 2009 Feb;116(2):286-96. doi: 10.1016/j.ophtha.2008.09.014. Epub 2008 Dec 16. Ophthalmology. 2009. PMID: 19091408

3

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, Gibson A, Sy J, Rundle AC, Hopkins JJ, Rubio RG, Ehrlich JS; RISE and RIDE Research Group. Nguyen QD, et al. Among authors: gibson a. Ophthalmology. 2012 Apr;119(4):789-801. doi: 10.1016/j.ophtha.2011.12.039. Epub 2012 Feb 11. Ophthalmology. 2012. PMID: 22330964 Clinical Trial.

4

A comparison of lamellar and penetrating keratoplasty outcomes: a registry study.

Coster DJ, Lowe MT, Keane MC, Williams KA; Australian Corneal Graft Registry Contributors. Coster DJ, et al. Ophthalmology. 2014 May;121(5):979-87. doi: 10.1016/j.ophtha.2013.12.017. Epub 2014 Feb 1. Ophthalmology. 2014. PMID: 24491643

5

Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.

Do DV, Nguyen QD, Vitti R, Berliner AJ, Gibson A, Saroj N, Soo Y, Boyer DS. Do DV, et al. Among authors: gibson a. Ophthalmology. 2016 Apr;123(4):850-7. doi: 10.1016/j.ophtha.2015.11.008. Epub 2016 Jan 28. Ophthalmology. 2016. PMID: 26832658 Clinical Trial.

6

Effect of Fluid Status at Week 12 on Visual and Anatomic Outcomes at Week 52 in the VIEW 1 and 2 Trials.

Moshfeghi DM, Hariprasad SM, Marx JL, Thompson D, Soo Y, Gibson A, Saroj N, Vitti R, Heier JS. Moshfeghi DM, et al. Among authors: gibson a. Ophthalmic Surg Lasers Imaging Retina. 2016 Mar;47(3):238-44. doi: 10.3928/23258160-20160229-06. Ophthalmic Surg Lasers Imaging Retina. 2016. PMID: 26985797 Clinical Trial.

7

Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials.

Kitchens JW, Do DV, Boyer DS, Thompson D, Gibson A, Saroj N, Vitti R, Berliner AJ, Kaiser PK. Kitchens JW, et al. Among authors: gibson a. Ophthalmology. 2016 Jul;123(7):1511-20. doi: 10.1016/j.ophtha.2016.02.046. Epub 2016 Apr 12. Ophthalmology. 2016. PMID: 27084563 Review.

8

Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.

Jaffe GJ, Kaiser PK, Thompson D, Gibson A, Saroj N, Vitti R, Berliner AJ, Heier JS. Jaffe GJ, et al. Among authors: gibson a. Ophthalmology. 2016 Sep;123(9):1856-64. doi: 10.1016/j.ophtha.2016.05.016. Epub 2016 Jun 28. Ophthalmology. 2016. PMID: 27369111 Free article. Clinical Trial.

9

Intravitreal Aflibercept Injection in Eyes With Substantial Vision Loss After Laser Photocoagulation for Diabetic Macular Edema: Subanalysis of the VISTA and VIVID Randomized Clinical Trials.

Wykoff CC, Marcus DM, Midena E, Korobelnik JF, Saroj N, Gibson A, Vitti R, Berliner AJ, Williams Liu Z, Zeitz O, Metzig C, Schmelter T, Heier JS. Wykoff CC, et al. Among authors: gibson a. JAMA Ophthalmol. 2017 Feb 1;135(2):107-114. doi: 10.1001/jamaophthalmol.2016.4912. JAMA Ophthalmol. 2017. PMID: 28006063

10

Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis.

Hernandez L, Lanitis T, Cele C, Toro-Diaz H, Gibson A, Kuznik A. Hernandez L, et al. Among authors: gibson a. J Manag Care Spec Pharm. 2018 Jul;24(7):608-616. doi: 10.18553/jmcp.2018.24.7.608. J Manag Care Spec Pharm. 2018. PMID: 29952707 Free PMC article.

Given the similar efficacy and safety profiles between IAI and ranibizumab, their associated costs and comparative cost-effectiveness are key factors in determining which one represents a more rational investment of scarce health care resources to help address the increasi …

Given the similar efficacy and safety profiles between IAI and ranibizumab, their associated costs and comparative cost-effectiveness are ke …

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,024 results

Search Page

Filters